These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 16243821)

  • 1. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
    J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
    Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
    Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
    J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Amin A; Benavides LC; Holmes JP; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Storrer CE; Jama YH; Craig D; Stojadinovic A; Ponniah S; Peoples GE
    Cancer Immunol Immunother; 2008 Dec; 57(12):1817-25. PubMed ID: 18392824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
    Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
    Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL; Schiffman K; Cheever MA; Disis ML
    Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
    Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
    Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
    Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
    Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
    Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
    Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
    Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
    Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
    Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.